Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects

被引:112
|
作者
Doose, DR
Wang, SS
Padmanabhan, M
Schwabe, S
Jacobs, D
Bialer, T
机构
[1] Hebrew Univ Jerusalem, Dept Pharmaceut, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
topiramate; carbamazepine; ethinyl estradiol; norethidrone; obesity;
D O I
10.1046/j.1528-1157.2003.55602.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To study the pharmacokinetics of a combination oral contraceptive (OC) containing norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure. Methods: This randomized, open-label, five-group study included two 28-day cycles. Five groups of female subjects received oral doses of ORTHO-NOVUM 1/35 alone (cycle 1) and then concomitant with TPM or CBZ (cycle 2). The treatment groups were group 1, TPM, 50 mg/day; group 2, TPM, 100 mg/day; group 3, TPM, 200 mg/day; group 4, TPM, 200 mg/day (obese women); and group 5, CBZ, 600 mg/day. Group 4 comprised obese women whose body mass index (BMI) was between 30 and 35 kg/m(2). The BMI of the remaining four groups was less than or equal to27 kg/m(2). Results: Coadministration of TPM at daily doses of 50, 100, and 200 mg (nonobese) and 200 mg (obese) nonsignificantly (p > 0.05) changed the mean area under the curve (AUC) of ethinyl estradiol by -12%, +5%, -11%, and -9%, respectively, compared with OC monotherapy. A similar nonsignificant difference was observed with the plasma levels and AUC values of norethindrone (p > 0.05). CBZ (600 mg/day) significantly (p < 0.05) decreased the AUC values of norethindrone and ethinyl estradiol by 58% and 42%, respectively, and increased their respective oral clearance by 69% and 127% (p < 0.05). Because CBZ induces CYP 3A-mediated and glucuronide conjugation metabolic pathways, the significant increase in the oral clearance of ethinyl estradiol and norethindrone was anticipated. Conclusions: TPM, at daily doses of 50-200 mg, does not interact with an OC containing norethindrone and ethinyl estradiol. The lack of the TPM-OC interaction is notable when it is compared with the CBZ-OC interaction.
引用
收藏
页码:540 / 549
页数:10
相关论文
共 50 条
  • [31] Absence of clinically significant drug interactions with coadministration of atogepant and an ethinyl estradiol/levonorgestrel oral contraceptive in healthy female subjects: a phase 1 pharmacokinetic analysis
    Ankrom, W.
    Xu, J.
    Vallee, M-H.
    Dockendorf, M. F.
    Armas, D.
    Boinpally, R.
    Min, K. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 420 - 420
  • [32] Absence of Clinically Significant Drug Interactions With Coadministration of Ubrogepant and an Ethinyl Estradiol/Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
    Li, Chi-Chung
    Palcza, John
    Xu, Jialin
    Thornton, Bob
    Ankrom, Wendy
    Jakate, Abhijeet
    Marcantonio, Eugene E.
    NEUROLOGY, 2019, 92 (15)
  • [33] Absence of Clinically Significant Drug Interactions with Coadministration of Ubrogepant and an Ethinyl Estradiol/Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
    Li, C.
    Palcza, J.
    Xu, J.
    Thornton, B.
    Ankrom, W.
    Jakate, A.
    Marcantonio, E. E.
    HEADACHE, 2019, 59 : 91 - 91
  • [34] PROSPECTIVE-STUDY OF CARBOHYDRATE-METABOLISM IN WOMEN USING A TRIPHASIC ORAL-CONTRACEPTIVE CONTAINING NORETHINDRONE AND ETHINYL ESTRADIOL FOR 3 MONTHS
    SPELLACY, WN
    ELLINGSON, AB
    KOTLIK, A
    TSIBRIS, JCM
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 159 (04) : 877 - 879
  • [35] THE EFFECTS OF MULTIPLE DOSES OF CANAGLIFLOZIN ON THE PHARMACOKINETICS AND SAFETY OF SINGLE DOSES OF AN ORAL CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND LEVONORGESTREL.
    Skee, D.
    Shalayda, K.
    Vandebosch, A.
    Usiskin, K.
    Tickel-Logan, R.
    Devineni, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S35 - S35
  • [36] Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradjol (Ortho-Novum® 1/35) in healthy adult female subjects.
    Karim, A.
    Copa, A.
    Fleck, P.
    Helland, J.
    Munsaka, M.
    Mekki, Q.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S14 - S14
  • [37] Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers
    Menon, Sujatha
    Riese, Richard
    Wang, Ronnie
    Alvey, Christine W.
    Shi, Haihong
    Petit, Wendy
    Krishnaswami, Sriram
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (05): : 336 - 342
  • [38] Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects
    Andrews, Emma
    Damle, Bharat D.
    Fang, Annie
    Foster, Grover
    Crownover, Penelope
    LaBadie, Robert
    Glue, Paul
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (04) : 531 - 539
  • [39] Effect of a combined oral contraceptive containing 20μg ethinyl estradiol and 75μg gestodene on hemostatic parameters
    Aldrighp, JM
    De Campos, LSC
    Gebara, OCE
    Petta, CA
    Bahamondes, L
    GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (01) : 1 - 4
  • [40] Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl estradiol on the human endometrium
    Lüdicke, F
    Johannisson, E
    Helmerhorst, FM
    Campana, A
    Foidart, JM
    Heithecker, R
    FERTILITY AND STERILITY, 2001, 76 (01) : 102 - 107